Format

Send to

Choose Destination
Oncotarget. 2015 Apr 30;6(12):10460-72.

Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3.

Author information

1
Division of Hematology, Institute of Molecular Hematology, The Second Xiang-ya Hospital, Central South University, Changsha, Hunan, China.
2
Division of Hematology, The First Affiliated Hospital, Lanzhou University, Lanzhou, Gansu, China.

Abstract

Icaritin is an active prenylflavonoid derived from Epimedium genus, a traditional Chinese medicine. Icaritin has a wide range of pharmacological and biological activities, including cardiovascular function improvement, hormone regulation and antitumor activity. Here, we investigated the effect of icaritin on multiple myeloma (MM) in vitro and in vivo. Icaritin inhibited cell growth of MM cell line and primary MM cells. In contrast, icaritin had low or no cytotoxic effect on normal hematopoiesis. We also demonstrated that in MM xenograft mouse models, icaritin suppressed tumor growth and decreased serum IL-6 and IgE levels, but did not show adverse reactions such as body weight loss. The anti-MM activity of icaritin was mainly mediated by inhibiting IL-6/JAK2/STAT3 signaling. We suggest that icaritin can be further tested in clinical trials in MM.

KEYWORDS:

IL6/JAK2/STAT3 signaling; antitumor activities; icaritin; multiple myeloma

PMID:
25865044
PMCID:
PMC4496367
DOI:
10.18632/oncotarget.3399
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center